aibioStandard BioTools gets Nasdaq minimum bid price notice, has until January 19, 2027
Tickers LAB
Nasdaq told Standard BioTools on July 22, 2026 that its shares closed below $1.00 for 30 days. The company has until January 19, 2027 to regain compliance, and its own filing says it cannot be sure it will.
Key facts
- Company
- Labiana Health SA (BME: LAB)
- News type
- Listings
- Primary source
- STANDARD BIOTOOLS INC. Form 8-K filed July 24, 2026 (SEC EDGAR)
Standard BioTools Inc. (Nasdaq: LAB) received a Nasdaq deficiency notice on July 22, 2026 because its common stock did not meet the minimum bid price requirement for continued listing on The Nasdaq Global Select Market. The company has until January 19, 2027 to regain compliance. It disclosed the notice in a Form 8-K filed July 24, 2026.
What the notice says
The letter came from the Listing Qualifications Department of The Nasdaq Stock Market LLC, which the filing calls the Staff. It says the company did not meet Nasdaq Listing Rule 5450(a)(1), the minimum bid price requirement, after a 30-day period in which the share price closed below the $1.00 threshold. Under Nasdaq Listing Rule 5810(c)(3)(A), that run of closes below $1.00 triggers an automatic compliance period of 180 calendar days.
The 8-K does not say how far below $1.00 the shares closed on any day, and it does not give a closing price for the filing date. The company says the notice has no immediate effect on the listing or trading of its common stock, which continues to trade on Nasdaq under the ticker "LAB". It also says the notice does not affect its operations or its reporting obligations with the Securities and Exchange Commission.
The deadline and the fallbacks
To regain compliance, the stock must close at or above $1.00 for a minimum of 10 consecutive business days before January 19, 2027. The 8-K does not describe any step the company has taken toward that result.
A second window is possible but conditional. If the company meets every other continued listing standard for The Nasdaq Global Select Market, it may receive an additional 180-day period, unless the Staff uses its discretion to shorten the ten-day test under Rule 5810(c)(3)(H). To take that route, the company would have to transfer its listing to The Nasdaq Capital Market, meet the market value of publicly held shares requirement, pay a Nasdaq application fee, and tell the Staff in writing that it intends to cure the deficiency during the extra period. The filing gives a reverse stock split as one example of how it could cure the deficiency, if needed. It does not say whether the company plans one.
The company says it "intends to work toward restoring compliance within the prescribed timeframe." The same filing adds that "there can be no assurance" it will regain compliance, or that the Staff will grant a further extension if one applies.
The business behind the notice
The notice arrives at a company that has been reshaping itself. On June 22, 2025, Standard BioTools agreed to sell its aptamer-based proteomics business, the SomaScan Business, to Illumina, Inc. The sale closed on January 30, 2026. The company's 2025 annual report on Form 10-K treats the SomaScan Business as a discontinued operation. It says the company kept its mass cytometry and microfluidics businesses, and names CyTOF, Hyperion and Biomark as its continuing platforms.
Revenue from customers outside the United States was $56.9 million, or 67% of total revenue, in 2025, according to the same report. The board authorized a share repurchase of up to $50.0 million in February 2024, running through March 1, 2026. By December 31, 2025, the company had bought back 15,448,533 shares for an aggregate $40.5 million under that program. It did not repurchase any shares during 2025.
The 10-K also describes a suit filed on July 2, 2025 by Shareholder Representative Services LLC, which the filing calls SRS, on behalf of the former securityholders of Palamedrix, Inc. SRS alleges that SomaLogic, a subsidiary that Illumina bought, failed to keep investing in Palamedrix technology. It claims SomaLogic would have owed up to $17.5 million in three sales-based milestone payments had that technology been commercialized. SomaLogic moved to compel arbitration on August 4, 2025. The court denied that motion, and the case moves into discovery. The allegations are SRS's, and the filing does not report a ruling on the merits.
Chief Financial Officer Alex Kim signed the 8-K for the company on July 24, 2026.